SGMO
NASDAQ
US
Sangamo Therapeutics, Inc. - Common Stock
$0.30
▲ +$0.04
(+15.38%)
Vol 8.8M
1
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$141.3M
ROE
-814.0%
Margin
-331.3%
D/E
0.00
Beta
1.29
52W
$0–$3
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
72.7%
Buy Rating
Price Chart
Similar Stocks
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
CADL
Candel Therapeutics Inc
$310.2M
ALDX
Aldeyra Therapeutics Inc
$99.9M
Earnings
Beat rate: 20.0%
Next Report
May 11, 2026
EPS Estimate: $0.01
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.01 | — | — |
| Dec 2025 | $-0.06 | $-0.11 | $-0.05 |
| Sep 2025 | $0.00 | $-0.11 | $-0.11 |
| Jun 2025 | $-0.13 | $-0.08 | +$0.05 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -293.1% | -293.1% | -293.1% | -293.1% | -814.0% | -814.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -109.2% | -77.5% | -77.5% | -77.5% | -331.3% | -331.3% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.05 | 1.05 | 1.05 | 1.05 | 0.88 | 0.88 |
Key Ratios
ROA (TTM)
-116.5%
P/S (TTM)
4.30
P/B
9.3
EPS (TTM)
$-0.44
CF/Share
$-1.36
Rev Growth 3Y
-19.5%
52W High
$2.73
52W Low
$0.38
$0.38
52-Week Range
$2.73
How does SGMO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SGMO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.3
▼
67%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
9.4
▲
280%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SGMO profitability vs Biotechnology peers
ROE
-814.0%
▼
1109%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-331.3%
▼
16%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-116.5%
▼
149%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
SGMO financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
0.9
▼
80%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.3
▲
33%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
SGMO fundamentals radar
SGMO
Peer median
Industry
SGMO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SGMO vs peers: key metrics
Latest News
No related news yet